A new paper in Science by Bert Vogelstein suggests that a good part of cancer is attributable to bad luck. There are so many big questions about cancer. They resonate with me very strongly as a cancer researcher and a cancer survivor myself (more on my cancer story here). What really causes cancer? Why does […]
Review of Bert Vogelstein “Bad Luck” Cancer Science pub Read More »
The Japanese research institute RIKEN has come full circle in a way on the STAP cell scandal. Note that the STAP papers included not only authors from RIKEN, but also from Brigham and Women’s Hospital/Harvard Medical School. With its final report released today (also a powerpoint of images were released including the one showing a
Perspectives on final RIKEN report on STAP cell scandal & what comes next Read More »
The Niche is the top, most authoritative stem cell and regenerative medicine blog on the web and the only one to our knowledge written by a professor. It is mainly written by Professor Paul Knoepfler of UC Davis School of Medicine, an internationally respected stem cell biologist and educator. Knoepfler is an advocate of rigorous
About Us, The Niche and Knoepfler Lab Read More »
How does one go about cheating death? Who doesn’t want to cheat death? I know I certainly do. Can stem cells help many people in the immediate future to escape death (pictured here in personified form as Death t from Wikipedia)? Recent headlines on new stem cell-related clinical developments would make you think so and
The cheating death excitation Read More »
CIRM issued a press release (PR) a few days ago unveiling CIRM 2.0, a new form of the agency and funding of novel efforts. The PR focused on action by its Governing Board to fund three Alpha Clinic programs for $8 million each at City of Hope (LA), UCLA, and UCSD. The Alpha Clinics will
CIRM 2.0 Launches Alpha Clinics & Continues Bridges Program Read More »
I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has
Shinya Yamanaka Interview on Clinical Use of IPSC Read More »
I had the idea of something called Prostate cancer postcards. In a few days it will be the 5-year anniversary of my diagnosis with a very serious form of prostate cancer. So far since then I’ve been doing pretty well (knock on wood). I am still getting PSA tested and life still has a cancer thread
Prostate cancer postcards Read More »
The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related
Advanced Cell Technology pub: Trial for Macular Degeneration Read More »
Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based
BioTime Cell Cure Files IND with FDA for ES cell AMD therapy Read More »
The California Stem Cell Agency CIRM seems to be in budget cutting mode these days, which from a general perspective makes sense as CIRM seeks to continue operating on its remaining funding through a longer period of time as far out as to 2020. However, not all cuts are necessarily positive. For example, CIRM reportedly (note: many
CIRM 2.0 Should Include Bridges Training Program Read More »